Patent intelligence · WO
WO 2022074143
DÉRIVÉS DE BENZO[H]QUINAZOLIN-4-AMINE ET DE THIÉNO[3,2-H]QUINAZOLIN-4-AMINE POUR LE TRAITEMENT DU CANCER
DÉRIVÉS DE BENZO[H]QUINAZOLIN-4-AMINE ET DE THIÉNO[3,2-H]QUINAZOLIN-4-AMINE POUR LE TRAITEMENT DU CANCER
Patent details — WO 2022074143
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Apr 14, 2022
- Expiration
- Apr 9, 2042
- Applicant
- BASILEA PHARM INT AG [CH]
- CPC classes
- A61K 31/ 505 A I, A61K 31/ 517 A I, A61K/31517, A61P 35/ 00 A I
Quick answer
WO 2022074143 (DÉRIVÉS DE BENZO[H]QUINAZOLIN-4-AMINE ET DE THIÉNO[3,2-H]QUINAZOLIN-4-AMINE POUR LE TRAITEMENT DU CANCER) is held by BASILEA PHARM INT AG [CH]. Status: granted. Granted Apr 14, 2022. Expires Apr 9, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BASILEA PHARM INT AG [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 505 A I, A61K 31/ 517 A I, A61K/31517, A61P 35/ 00 A I, A61P/3500
More from BASILEA PHARM INT AG [CH]
Related pharmaceutical patents in our USPTO index.
-
AU 2024384453
CITRATE COORDINATION COMPLEX OF AN ORALLY-DELIVERED BETA-LACTAMASE INHIBITOR AND USES THEREOF
granted -
PT 3886798
COMBINATION COMPOSITIONS COMPRISING A BETA-LACTAMASE INHIBITOR AND USES THEREOF
granted -
US 20260042800
ANTIMICROBIAL PEPTIDOMIMETICS
granted -
WO 2025114603
COMBINAISONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT D'INFECTIONS FONGIQUES
granted -
WO 2024094329
PRÉPARATION DE CAPSULE SOUS EMBALLAGE COQUE CONTENANT DU SULFATE D'ISAVUCONAZONIUM
granted -
CA 3268414
MÉTHODES DE TRAITEMENT D'INFECTIONS AVEC BACTÉRIÉMIE À STAPHYLOCOCCUS AUREUS
granted -
AU 2022323463
ANTIMICROBIAL PEPTIDOMIMETICS
granted -
AR 127448
DERIVADOS DE BENZO[H]QUINAZOLIN-4-AMINA PARA EL TRATAMIENTO DEL CÁNCER
granted
Frequently asked questions
What is US patent 2022074143?
WO 2022074143 (DÉRIVÉS DE BENZO[H]QUINAZOLIN-4-AMINE ET DE THIÉNO[3,2-H]QUINAZOLIN-4-AMINE POUR LE TRAITEMENT DU CANCER) is held by BASILEA PHARM INT AG [CH]. Status: granted. Granted Apr 14, 2022. Expires Apr 9, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2022074143?
BASILEA PHARM INT AG [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2022074143 expire?
Our index shows an expiration date of Apr 9, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.